These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27898730)

  • 21. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.
    Lee HY; Walsh SA; Creamer D
    Br J Dermatol; 2017 Oct; 177(4):924-935. PubMed ID: 28144971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive Assessment of Long-Term Complications in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Cekic S; Canitez Y; Yuksel H; Ucan Gunduz G; Karali Z; Yalcinbayir O; Vural P; Sapan N
    Int Arch Allergy Immunol; 2023; 184(10):994-1002. PubMed ID: 37494888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population.
    Jun I; Rim JH; Kim MK; Yoon KC; Joo CK; Kinoshita S; Seo KY; Ueta M
    Br J Ophthalmol; 2019 Apr; 103(4):573-576. PubMed ID: 30705045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Sotozono C; Ueta M; Nakatani E; Kitami A; Watanabe H; Sueki H; Iijima M; Aihara M; Ikezawa Z; Aihara Y; Kano Y; Shiohara T; Tohyama M; Shirakata Y; Kaneda H; Fukushima M; Kinoshita S; Hashimoto K;
    Am J Ophthalmol; 2015 Aug; 160(2):228-237.e2. PubMed ID: 25979679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing.
    Nakatani K; Ueta M; Khor SS; Hitomi Y; Okudaira Y; Masuya A; Wada Y; Sotozono C; Kinoshita S; Inoko H; Tokunaga K
    Sci Rep; 2019 Nov; 9(1):16240. PubMed ID: 31700100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications-phenotypes and genetic predispositions.
    Ueta M
    Taiwan J Ophthalmol; 2016; 6(3):108-118. PubMed ID: 29018724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
    Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
    Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications.
    Ueta M; Sotozono C; Inatomi T; Kojima K; Hamuro J; Kinoshita S
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1809-13. PubMed ID: 18263811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
    Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
    Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic ocular complications in lamotrigine vs. trimethoprim-sulfamethoxazole induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Rashad R; Shanbhag SS; Kwan J; Chodosh J; Saeed S; Saeed HN
    Ocul Surf; 2021 Jul; 21():16-18. PubMed ID: 33932610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage.
    Sotozono C; Ueta M; Yokoi N
    Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES80-DES86. PubMed ID: 30481810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series.
    Yip LW; Thong BY; Lim J; Tan AW; Wong HB; Handa S; Heng WJ
    Allergy; 2007 May; 62(5):527-31. PubMed ID: 17313402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Van Zyl L; Carrara H; Lecuona K
    Middle East Afr J Ophthalmol; 2014; 21(4):332-5. PubMed ID: 25371640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
    Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
    Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrolysis in the UK population.
    Butt GF; Hassan A; Wallace GR; Kinoshita S; Ahmad S; Ueta M; Rauz S
    Sci Rep; 2021 Feb; 11(1):2928. PubMed ID: 33536518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Sadek M; Iqbal O; Siddiqui F; Till S; Mazariegos M; Campbell E; Mudaliar K; Speiser J; Bontekoe E; Kouta A; Farooqui A; Daravath B; Qneibi D; Sadek R; Hoppensteadt D; Fareed J; Bouchard C
    Clin Appl Thromb Hemost; 2021; 27():1076029620950831. PubMed ID: 33560872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Carr DF; Wang CW; Bellón T; Ressel L; Nwikue G; Shrivastava V; Bergfeld W; Jorgensen AL; Chung WH; Pirmohamed M
    Br J Dermatol; 2019 Jul; 181(1):166-174. PubMed ID: 30613954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.
    Gao X; Tang X; Ai L; Gao Q; Liao Q; Chen M; Chen X; Zhou H; Ye Y; Li M; Han J; Wang F
    J Am Acad Dermatol; 2021 Mar; 84(3):644-653. PubMed ID: 32561372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.